| 1 |
Les I, Martínez M, Pérez-Francisco I, Cabero M, Teijeira L, Arrazubi V, Torrego N, Campillo-Calatayud A, Elejalde I, Kochan G, Escors D. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers (Basel) 2023;15. [PMID: 36900420 DOI: 10.3390/cancers15051629] [Reference Citation Analysis]
|
| 2 |
Ramanathan S, Brilot F, Irani SR, Dale RC. Origins and immunopathogenesis of autoimmune central nervous system disorders. Nat Rev Neurol 2023;19:172-90. [PMID: 36788293 DOI: 10.1038/s41582-023-00776-4] [Reference Citation Analysis]
|
| 3 |
Jiang N, Yu Y, Wu D, Wang S, Fang Y, Miao H, Ma P, Huang H, Zhang M, Zhang Y, Tang Y, Li N. HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events. J Cancer Res Clin Oncol 2023;149:737-47. [PMID: 36662304 DOI: 10.1007/s00432-022-04493-1] [Reference Citation Analysis]
|
| 4 |
Imai S, Mitsuboshi S, Hori S, Suzuki S. Increased risk of Lambert-Eaton myasthenic syndrome (LEMS) in small-cell lung cancer patients treated with immune checkpoint inhibitor. Eur J Cancer 2023;180:1-3. [PMID: 36527972 DOI: 10.1016/j.ejca.2022.11.023] [Reference Citation Analysis]
|
| 5 |
Gaspar BL. Current Concepts and Future Prospects in Immune-Mediated Neuropathies. Immune-Mediated Myopathies and Neuropathies 2023. [DOI: 10.1007/978-981-19-8421-1_20] [Reference Citation Analysis]
|
| 6 |
Wang S, Peng D, Zhu H, Min W, Xue M, Wu R, Shao Y, Pan L, Zhu M. Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. Front Oncol 2022;12:1053370. [PMID: 36568231 DOI: 10.3389/fonc.2022.1053370] [Reference Citation Analysis]
|
| 7 |
Ibrahim EY, Zhao WC, Mopuru H, Janowiecki C, Regelmann DJ. Hope, Cure, and Adverse Effects in Immunotherapy: Atezolizumab-Associated Encephalitis in Metastatic Small Cell Lung Cancer - A Case Report and Literature Review. Case Rep Neurol 2022;14:366-71. [PMID: 36824581 DOI: 10.1159/000526248] [Reference Citation Analysis]
|
| 8 |
Jiang N, Yu Y, Zhang M, Tang Y, Wu D, Wang S, Fang Y, Zhang Y, Meng L, Li Y, Miao H, Ma P, Huang H, Li N. Association between germ-line HLA and immune-related adverse events. Front Immunol 2022;13:952099. [DOI: 10.3389/fimmu.2022.952099] [Reference Citation Analysis]
|
| 9 |
Okiyama N, Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int 2022;71:169-78. [PMID: 35101349 DOI: 10.1016/j.alit.2022.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 10 |
Satake T, Maruki Y, Kubo Y, Takahashi M, Ohba A, Nagashio Y, Kondo S, Hijioka S, Morizane C, Ueno H, Okusaka T. Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review. Intern Med . [DOI: 10.2169/internalmedicine.8919-21] [Reference Citation Analysis]
|
| 11 |
Orlova R, Zhukova N, Malkova A, Shoenfeld Y. Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy. Cancer Treatment and Research Communications 2022;31:100529. [DOI: 10.1016/j.ctarc.2022.100529] [Reference Citation Analysis]
|
| 12 |
Vogrig A, Muñiz-Castrillo S, Farina A, Honnorat J, Joubert B. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. J Neurol 2021. [PMID: 34708250 DOI: 10.1007/s00415-021-10870-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Ai L, Gao J, Zhao S, Li Q, Cui YH, Liu Q, Wu D, Wang Y, Jin X, Ji Y, Li J, Yu Y, Liu T. Nivolumab-associated DRESS in a genetic susceptible individual. J Immunother Cancer 2021;9:e002879. [PMID: 34599025 DOI: 10.1136/jitc-2021-002879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Seki M, Kitano S, Suzuki S. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. Cancer Immunol Immunother 2021. [PMID: 34515815 DOI: 10.1007/s00262-021-03053-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 15 |
Valencia-Sanchez C, Zekeridou A. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. Front Neurol 2021;12:642800. [PMID: 33897597 DOI: 10.3389/fneur.2021.642800] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 16 |
Atezolizumab. Reactions Weekly 2021;1838:85-85. [DOI: 10.1007/s40278-021-89404-7] [Reference Citation Analysis]
|
